Platelet Rich Plasma Market size is estimated to cross US$ 84.10 Million by 2032 | FMI
The market for Platelet Rich Plasma(PRP) in Europe is expected to reach US$ 37.5 Million in 2016, up from US$ 35.3 Million in 2015. Adoption of platelet-rich plasma in treating musculoskeletal injuries, including tennis elbow, Achilles tendinopathy, and plantar fasciitis, will continue to drive revenues. PRP therapy is also gaining traction in treating sports-related and geriatric injuries, owing to its minimally invasive procedure and quicker recovery time.
By product type, PRP kits will continue to outsell instruments, accounting for over 75% revenue share of the market in 2016. Among the various platelet-rich plasma kits, autologous kits will account for the highest demand on the basis of blood type, representing a market value worth US$ 24.2 Million. P-PRF kits—valued at US$ 10 Million in 2015—will witness the highest growth by end-product type, increasing at 8.6% in 2016.
Request Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-eu-1599
By application, the adoption of PRP therapy will continue to remain highest in the treatment of knee and elbow injuries. While knee application segment revenues will grow by 7.2%, elbow application segment revenues are projected to grow by 6.3%. The use of PRP therapy in the treatment of ever-increasing incidences of osteoarthritis and tennis elbow will gain further traction in 2016 and beyond.
PRP revenues in the UK—the largest market in Europe—will grow by 7.3% in 2016, an increase of 0.20% from the 7.1% growth in 2015. High prevalence of sports-related incidents in the U.K., combined with high awareness about the benefits of PRP therapy among healthcare community and patients, will continue to fuel the growth of the market in the country.
France will maintain its position as the second largest market for PRP in Europe, growing by 6.5% in terms of revenues in 2016. France is home to subsidiaries and distributors of several PRP players, such as Biomet, Inc., DePuy Synthes, Inc., and Stryker Corporation and a range of highly innovative products are available in the market.
Johnson & Johnson Inc. and Stryker Corporation are the established players in the Europe PRP market. Johnson & Johnson’s PEAK Platelet Rich Plasma System and Stryker Corporation’s RegenKit THT Autologous Platelet-rich Plasma (A-PRP) will continue to witness sizeable sales in 2016. Arthrex – Arthrex Angel System from Arthrex Inc. and GPS® III Platelet Separation System by Zimmer Biomet Holdings Inc. will also account for substantial revenue share of the Europe PRP market.
Ask the Analyst: https://www.futuremarketinsights.com/ask-question/rep-eu-1599
Long-term Outlook: The PRP market in Europe is expected to increase at a CAGR of 6.6% during the forecast period 2016-2024. The UK will continue to be at the forefront of overall demand, with France and Germany accounting for sizeable market share. While FMI maintains a positive outlook on the Europe PRP market, challenges, including lack of standardisation in preparation and dosage of autologous blood concentrate, and uncertainty about therapy efficacy can impede growth during the forecast period.
Drivers and Trends
The Europe PRP market was valued at US$ 35.3 Million in 2015, and is projected to grow at a CAGR of 6.6% over the forecast period 2016-2024 owing to rising demand for PRP therapy in sport injuries.
Platelet-rich Plasma (PRP) therapy is a minimally invasive procedure and an alternative option to surgery. PRP therapy is a quick and highly effective treatment for reducing the pain and enhances tissue regeneration power with less recovery time along with higher success rates. PRP treatment is very cost effective compared to surgical procedures for orthopedic and sports injuries.
Some major factors driving the growth of PRP market are expanding PRP application in the sports medicine industry, technological advancements in PRP therapy, progressive demographic ageing of the older population etc. These factors are expected to fuel the growth of the market growth rate over the forecast period.
Use promo code ->> FMITODAY to get a flat 20% discount
Key Segments Covered
- Kits BY Type
- Pure Platelet-Rich Plasma (P-PRP)
- Leukocyte-Rich Platelet-Rich Plasma (L-PRP)
- Leukocyte-Platelet-Rich Fibrin (L-PRF)
- Pure Platelet-Rich Fibrin (P-PRF)
- Kits BY Type
- Kits BY Origin
- Autologous Platelet-Rich Plasma
- Homologus Platelet-Rich Plasma
- Allogeneic Platelet-Rich Plasma
- Foot and Ankle
Key Countries Covered
- The U.K.
- Rest of Europe
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
For Sales Enquiries: email@example.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs